Last reviewed · How we verify
Group S
At a glance
| Generic name | Group S |
|---|---|
| Also known as | Systematic |
| Sponsor | Ondokuz Mayıs University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Conservative Treatment of Trigger Finger (NA)
- Accelerated TMS for Apathy in PD (NA)
- Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies (NA)
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
- Adaptation and RCT of Written Exposure Therapy for Adolescents (NA)
- Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver Disease - A Multicenter, Randomized, Open-label, Controlled Trial (NA)
- Canadian Critical Care Comparative Effectiveness Platform (PHASE3)
- Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Group S CI brief — competitive landscape report
- Group S updates RSS · CI watch RSS
- Ondokuz Mayıs University portfolio CI